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Abstract
Background: Problems in social functioning (e.g., unemployment, social isolation), are common in people with a
psychotic disorder. Social cognition is a treatment target to improve social functioning, as it is a proximal predictor
of social functioning. Social Cognition Training (SCT) improves social cognition, but may not generalize (enduringly)
to social functioning, perhaps due to insufficient opportunity to practice in daily-life social situations. Using virtual
reality (VR) for SCT could address this problem, as VR is customizable, accessible, and interactive. We will test the
effect of a VR SCT, ‘DiSCoVR’, on social cognition and social functioning in a randomized controlled trial (RCT).
Methods: In total 100 people with a psychotic disorder and deficits in social cognition will be recruited for this
multicenter randomized controlled trial (RCT). Participants will be randomized to VR SCT (DiSCoVR) or VR relaxation
training (VRelax; active control). DiSCoVR is a 16-session individual SCT, consisting of three modules: 1) emotion
perception (recognizing facial emotions in a virtual shopping street); 2) social perception and theory of mind
(observing social interactions between virtual characters and assessing their behavior, emotions and thoughts); and
3) application of higher-order social cognition in social interaction (role-playing personalized situations in VR).
People receiving VRelax complete sixteen individual sessions, in which they receive psycho-education about stress,
identify personal stressors, learn relaxation techniques, and explore relaxing immersive virtual environments.
Assessments will be performed at baseline, post-treatment, and 3-month follow-up. Primary outcomes are emotion
perception (Ekman 60 Faces), social perception and theory of mind (The Awareness of Social Inference Test).
Secondary outcomes include social functioning (Personal and Social Performance Scale), experiences and social
interactions in daily life (experience sampling of emotions, social participation and subjective experience of social
situations), psychiatric symptoms (e.g., depression, perceived stress, anxiety, positive and negative symptoms) and
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self-esteem.
Discussion: To our knowledge, this will be the first RCT testing the efficacy of VR SCT. It will also investigate
generalization to daily life social situations, the durability of treatment effects, and moderators and mediators of
treatment success.
Trial registration: On December 5, 2017, this trial was registered prospectively in the Dutch Trial Register as NTR6863.
Keywords: Social cognition training, Virtual reality, Emotion perception, Theory of mind, Psychotic disorder,
Social functioning
Background
For many people who have a psychotic disorder, it is a
challenge to have meaningful daily activities, such as
work, and to develop and maintain personal and roman-
tic relationships; many of them experience problems in
social functioning [1]. To function in daily life, it is ne-
cessary to adequately handle social situations and to be
able to interpret the emotions, thoughts, intentions and
behaviors of other people. These capabilities are gener-
ally referred to as social cognition. However, in people
with a psychotic disorder, deficits in social cognition are
common; a meta-analysis found large deficits in emotion
perception and processing, social perception and theory
of mind, compared to healthy controls [2]. Deficits in
these key domains have been found to be important,
proximal predictors for social functioning [3]. Social
cognition has therefore become a target for psychosocial
interventions aiming to improve social functioning
through social cognitive training [4], a class of interven-
tions also known as social cognition training (SCT).
SCT aims to improve social cognition, and ultimately
social functioning through repeated practice with social
stimuli (e.g., identifying emotions in pictures of faces),
and compensatory strategy training (e.g., verbalization of
salient facial features) [5]. A meta-analysis [6] of all types
of SCT found large effects on emotion perception (rec-
ognition of emotions), and small to moderate effects on
theory of mind (the ability to recognize and reflect on
others’ mental states). A more recent meta-analysis [7],
including only comprehensive forms of SCT (i.e., target-
ing multiple areas of social cognition), found a large ef-
fect on emotion perception and theory of mind, and a
small to moderate effect on attribution style (judgments
about the causes of events and others’ behavior). To-
gether, these meta-analyses suggest that it is possible to
improve social cognition with SCT in people with a
psychotic disorder.
Some concerns have been raised, however, about the dur-
ability and generalizability of effects of SCT [4, 8]. While
one meta-analysis [6] found a positive effect of SCT on
community functioning, other reviews point out that treat-
ment effects are most commonly and robustly found for
lower-order social cognition processes such as emotion
perception. On higher-order social cognition such as theory
of mind, and social functioning, findings are more mixed
and dependent on the specific measure used [4, 8]. We
know from cognitive remediation research that integration
with daily life is important for skills developed though cog-
nitive training to generalize to social functioning [9]. Con-
ventional SCT approaches may offer insufficient
opportunity to practice in situations resembling real-life so-
cial interactions [8, 10]. Thus, effects of SCT on higher-
order social cognitive processes and social functioning may
be limited, as training materials may not sufficiently capture
the complex, interactive and dynamic nature of real-life so-
cial situations.
The utilization of virtual reality (VR) for SCT has been
proposed as a possible way to address this issue [4, 10].
VR is highly immersive, interactive and dynamic, and
elicits psychological reactions similar to those in daily
life [11]. Therefore, it is well-suited to simulate a variety
of social situations and adequately reflect their complex-
ity. At the same time, VR is controllable, which facili-
tates structured practice, and allows for situations to be
scripted, repeated, varied, and personalized. Moreover,
VR is a safe, accessible way to practice; participants
know the virtual interactions can be stopped at any time,
and that they can practice without negative repercus-
sions and fear of embarrassment in their real social lives.
Finally, VR is practical, as a wide range of situations can
be generated quickly and practiced from one treatment
setting, without traveling or accompanying participants
in their daily environment.
VR is therefore a promising method to provide SCT.
However, to our knowledge, no controlled studies of VR
SCT for people with a psychotic disorder are available.
Only one study on VR SCT has been published; a case
report with two participants [12]. Improvements in so-
cial cognition and social functioning were reported after
twenty sessions of a VR SCT. VR has also been used for
social skills training (SST) in people with psychosis. A
RCT of VR SST [13] among inpatients with schizophre-
nia (n = 91) showed that, compared to conventional SST,
VR SST produced greater improvements in assertiveness
and conversational skills, but no improvement was
found in non-verbal skills. A pilot study of VR SST [14]
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reported improvement in social functioning, and VR
measures revealed improvements in emotion perception,
assertiveness, and time spent in conversations. Finally,
pilot studies of VR SCT in people with autism spectrum
disorder have reported improved emotion perception
[15–17], attribution [16], theory of mind [15, 17], and
(self-reported) social functioning [17]. Together, these
studies suggest that VR SCT is promising.
To this end, we developed a novel VR SCT, Dynamic
Interactive Social Cognition Training in Virtual Reality
(DiSCoVR). In this randomized controlled trial (RCT),
we aim to compare DiSCoVR to an active control condi-
tion, i.e., VR relaxation training (VRelax), in order to
evaluate its efficacy on social cognition and social func-
tioning. Moreover, we aim to assess the impact of the
intervention on (the frequency and experience of) daily
life social interactions, by using Experience Sampling
Methodology (ESM), a diary method. We will also assess
the durability of potential treatment effects in a 3-month
follow-up period. Finally, we will perform moderator
analysis to investigate who benefits from this VR SCT,
and mediator analyses to examine variables mediating
treatment effects. Thus, this study is the first RCT on
VR SCT, using conventional measures of social cogni-
tion and functioning as well as experience sampling.
Methods/design
Participants
Participants are recruited from Dutch mental health
treatment centers (University Center of Psychiatry of the
University Medical Center Groningen, GGZ Drenthe,
GGZ Delfland, and Zeeuwse Gronden). We recruit par-
ticipants in two ways: 1) through advertisement of the
study, by distributing posters and flyers, allowing partici-
pants to enroll themselves; and 2) through clinician re-
ferral: clinicians refer eligible and interested participants.
Inclusion criteria are:
 A diagnosis of a psychotic disorder according to
DSM-5 criteria, either determined by a structured
clinical interview (e.g., Mini-international
Neuropsychiatric Interview [18], Structured Clinical
Interview for DSM [19], Schedules for Clinical
Assessment in Neuropsychiatry [20]) in the past
three years or verified using the MINI Plus at
baseline.
 Deficits in social cognition, as indicated by a
clinician.
 Age 18–65 years.
Exclusion criteria are:
 (Photosensitive) Epilepsy.
 An estimated IQ below 70, and/or a diagnosis of
intellectual disability.
 Insufficient proficiency in the Dutch language.
Participants receive a compensation of €30 for each
completed assessment, up to a total of €90. They also
receive reimbursement for travel expenses incurred
for the assessments.
Design
The CONSORT inclusion flow diagram is shown in
Fig. 1. This study is a multicenter single-blind random-
ized controlled trial (RCT) with two groups: 1) Dynamic
Interactive Social Cognition Training in Virtual Reality
(DiSCoVR), the experimental group; and 2) Virtual Real-
ity Relaxation (VRelax), an active control group. Both
groups receive treatment as usual alongside their desig-
nated intervention (DiSCoVR or VRelax). Participants
complete three assessments: before the intervention
(baseline, T0), directly after the intervention (post-treat-
ment, T1) and three months after completing the inter-
vention (follow-up, T2). After completion of the study,
participants have the opportunity to receive the other
treatment, if they wish.
Interventions
DiSCoVR
DiSCoVR is a 16-session individual VR SCT, taking
place twice a week over a period of eight weeks. DiS-
CoVR is provided by psychologists with (at minimum) a
master’s degree in clinical psychology. A detailed treat-
ment protocol describes the intervention, the software,
the techniques that are used and the content of each ses-
sion. Participants receive a workbook, containing session
content summaries, exercises and worksheets (e.g., regis-
tration form of emotions they identified in their daily
environment). DiSCoVR involves mass practice and
compensatory strategy training. References to the pa-
tient’s personal situations and goals are made in exam-
ples and/or exercises whenever possible, to facilitate
generalization of training material to daily life. To the
same end, through homework exercises, participants are
encouraged to practice with techniques and strategies
they have learned in the intervention in daily life. These
homework exercises are discussed at the start of each
session. The intervention consists of three parts, struc-
tured to build upon each other in increasing complexity:
 Module 1: Emotion perception (5 sessions, 1–5).
Participants explore a virtual shopping street where
they identify emotions on virtual characters’ faces.
Several characteristics (e.g., intensity of emotions,
time to respond) can be altered to adjust the
difficulty level to the training needs of the
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participant. Participants practice with several
strategies (e.g., mimicking emotions) to aid in
emotion recognition, which they are encouraged to
try at home.
 Module 2: Social perception & theory of mind (4
sessions, 6–9). Participants view scripted social
scenarios in VR, about which open-ended questions
regarding behavior, emotions and thoughts are
asked. These questions aim to stimulate
mentalization. Participants can respond by stating
their answer out loud. If they answer incorrectly,
characters will give more explicit hints about their
mental state, with intensified emotional expression.
Participants continue to apply social strategies to
understand situations (e.g., remembering how you
felt in a similar situation), by choosing a strategy
before practicing in VR. Participants learn about the
connection between thoughts, emotions and
behavior, and practice with recognizing these in VR
scenarios, themselves, and in others around them.
 Module 3: Social interaction (7 sessions, 10–16).
Participants apply social cognitive skills in VR
roleplay exercises with the therapist. They can
practice with situations they struggle with, or that
help them to achieve the goals they have set for the
intervention. The protocol provides sample roleplay
exercises, targeted at various social cognitive skills
(e.g., detection of sarcasm and hints). Outside of VR,
participants continue to practice with identifying
emotions, thoughts and behavior and understanding
their interrelatedness. They also learn a social
problem-solving technique, in which they 1)
consider their own thoughts, emotions and behavior;
2) consider the other person’s thoughts, emotions
and behavior; 3) consider different possible ways to
react to a situation; and 4) role-play the different
reactions and choose the most appropriate reaction
to carry out in real life. Participants continue to
practice using strategies (e.g., watching someone’s
emotional response to you to determine whether
you should talk to them), both in VR and in real life.
The immersive VR worlds (a shopping street, a super
market, an office and a bar), developed by CleVR BV,
are displayed with an Oculus Rift headset (Consumer
Version 1). They are shown in Fig. 2. Participants ex-
plore and interact with the virtual environment using a
joystick controller. For the role play exercises, voice
transformation is applied to mask the therapist’s real
voice. During the role plays, therapists can click buttons
on the computer interface to trigger emotions and/or
gesture animations (e.g., shrugging, pointing) in their
virtual character.
VRelax
As an active control group, we chose VRelax, a VR re-
laxation therapy, as it matched important nonspecific
characteristics of DiSCoVR (e.g., the use of VR, individ-
ual contact with a therapist twice a week), but did not
target sociocognitive processes and therefore was not ex-
pected to improve social cognition. VRelax consists of
sixteen sessions, provided twice a week in a period of
Fig. 1 CONSORT flow diagram
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eight weeks (the same as DiSCoVR), and aims to reduce
both momentary (during sessions) and daily life stress and
anxiety. VRelax is provided by therapists who either have
1) clinical experience in treating people with psychosis
(e.g., psychiatric nurses); or 2) at least a bachelor’s degree
in psychology. In VRelax, participants’ stressors are ex-
plored (i.e., which situations are stressful, and what are
signs of stress). Participants learn to recognize stressful
thoughts and rumination, and to apply coping strategies
to address these (e.g., solving problems, asking for support
and comfort, finding distraction). They also practice with
relaxation exercises, such as breathing exercises, a body
scan, grounding, and progressive muscle relaxation. Partici-
pants are encouraged to practice these techniques at home.
Each session starts with a discussion of stressors and
negative emotions in the past few days. In some sessions,
this is followed by psycho-education (e.g., about stress,
coping and rumination). A large portion (±25min) of
each session is reserved for relaxation in VR. Immersive
360° video clips are shown with a Samsung Gear VR
headset, running VRelax software developed by Viemr
BV. Participants can visit a range of relaxing environ-
ments (Fig. 3), such as a sea in which they can swim
with dolphins, a coral reef, a beach and a mountain
meadow. They can control the environment using gaze;
for example, to switch between environments or to en-
gage with interactive elements (e.g., popping air bubbles
underwater). Meditation exercises are embedded in the
VR environment (e.g., guided meditation). Finally, part of
each session is reserved for (learning to apply) relaxation
techniques. These can be skipped if participants prefer to
spend more time in VR.
Materials and measurement instruments
The measures used in this study are summarized in
Table 1.
Primary outcome
Facial affect recognition Ekman 60 Faces, Facial Ex-
pression of Emotions Stimuli and Tests (FEEST) [21].
60-item computerized picture test assessing facial affect
recognition. Participants view pictures of six emotions
(happy, sad, angry, disgusted, surprised, anxious) and
identify the expressed emotion. Total scores (0–60) are
used for analysis.
Social perception and theory of mind The Awareness
of Social Inference Test part III (TASIT, Dutch version)
[22, 23]. Short video clips showing social situations con-
taining lies and sarcasm. Participants answer four ques-
tions after each video about the intentions, intended
messages, beliefs and emotions of the characters. Total
scores (0–32) are used for analysis. Parallel versions are
used; the administration order (A-B-A or B-A-B) is ran-
domized across participants.
Secondary outcomes
Social functioning Personal and Social Performance
Scale (PSP) [24]. An interview assessing the degree of
disability (from 1, “absent”, to 5, “severe”) in four areas
of social functioning: 1) socially meaningful activities
(e.g., work, study); 2) personal and social relationships
(e.g., friendships); 3) self-care (e.g., hygiene); and 4)
Fig. 2 Pictures of DiSCoVR environments and set-up. Legend: Top left: module 1 (translation: which emotion? Angry, happy, surprised); top right:
module 2 (translation: what does Daniël actually mean?); bottom left: module 3, as seen from perspective of participant; bottom right: module 3,
interactive role play setup. The virtual environments are property of CleVR BV; images have been used with permission from CleVR BV
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disturbing and aggressive behavior (e.g., problems with
law enforcement). The ratings for each domain are com-
bined into one score from 0 (very low) to 100 (very
high), which will be used for analysis.
Momentary mental states and social functioning in
daily life Experience Sampling Method (ESM) dairies
are used to study the effects of the interventions on daily
life interactions. An online questionnaire (21–33 items,
included in Additional file 1: Table S1) is administered
ten times a day for seven days at semi-random moments,
by sending participants text messages containing a link
to the questionnaire, which they can complete in the
internet browser on a smartphone. Participants use their
own smartphone or one provided by the research team.
The ESM questionnaire assesses: 1) emotional state
(positive and negative affect and stress level; thirteen
items), on a visual analogue scale (VAS; 0–100); 2)
current activities and activities since the last question-
naire (five items, to assess social and societal participa-
tion), selected from a multiple choice menu, and a VAS
(0–100) on the enjoyability of the activity; 3) current so-
cial interactions and interactions since the last question-
naire (fourteen items), including the enjoyability of the
interaction, feelings of being accepted, knowing how to
respond, and feeling able to tell what the other person is
feeling (VAS, 0–100); and 4) taking social initiative (two
items; VAS, 0–100).
Psychiatric symptoms The following measures of psy-
chopathology will be administered, since (social) cogni-
tive training may improve psychiatric symptoms, and
symptom levels could be a moderator or mediator of
treatment effect:
 The Positive and Negative Syndrome Scale (PANSS)
[25], a semi-structured interview assessing positive
(7 items, range 7–49), negative (7 items, range 7–49)
and general (16 items, range 16–112) symptoms of
psychosis in the past week on a 7-point scale (from
1, “absent”, to 7, “very severe”). We will analyze the
three subscales separately as well as the total score.
 The Social Interaction Anxiety Scale (SIAS) [26], a
20-item self-report questionnaire measuring verbal
and non-verbal social anxiety on a 5-point Likert
scale. We will analyze the total score.
 The Green Paranoid Thought Scale (GPTS) [27], a
self-report questionnaire measuring paranoid
thoughts of social reference ([16] items, part A) and
social persecution (16 items, part B) in the past
Fig. 3 VRelax environments, including relaxation exercises. The virtual environments are property of Viemr BV; images have been used with
permission from Viemr BV
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month on a 5-point Likert scale. We will analyze
both subscales separately.
 Perceived Stress Scale (PSS) [28], a ten-item self-
report questionnaire on symptoms of stress in the
past week, indicated on a 5-point Likert scale. We
will analyze the total score.
Other
Self-esteem The Self-Esteem Rating Scale (SERS) [29].
The SERS is a twenty-item self-report questionnaire
using a 7-point Likert scale, assessing feelings of self-
worth and competence. Total scores will be analyzed.
Information processing and executive functioning
The Trailmaking Test (TMT) [30]. In TMT-A, partici-
pants connect numbers in circles scattered across a page
in consecutive order; in TMT-B, participants connect
numbers and letters in circles scattered across a page,
alternating between the letters and circles in consecutive
order (1-A-2-B, etc.). The completion time in seconds
for both parts is analyzed.
Demographic and clinical background Questions on
different clinical and demographic variables, including:
age, gender, handedness, eyesight, family history of psy-
chiatric illness, education level of participant and partici-
pant’s parents, work history, diagnosis and illness
duration (administered only at baseline); and housing
status, employment status, substance use, medication
use, hospitalizations and psychotic episodes (adminis-
tered at each assessment).
Premorbid intelligence The Dutch version (Neder-
landse Leestest voor Volwassenen, NLV) [31] of the Na-
tional Adult Reading Test [32]. Fifty increasingly
uncommon words are read aloud by participants. Cor-
rect pronunciations are awarded a score of two points.
Table 1 Measures used in this study
Domain Instrument Method Baseline (T0) Post-treatment (T1) Follow-up (T2)
Primary outcome measures
Emotion Perception Ekman 60 Faces (FEEST) Picture task x x x
Social Perception / ToM TASIT-III Video task x x x
Secondary outcome measures
Social functioning in daily life Questions about social interactions,
activities and momentary mental states
ESM questionnaire x x x
Social functioning PSP Interview x x x
Psychotic Symptoms PANSS Semi-structured
interview
x x x
Social Anxiety SIAS Questionnaire x x x
Paranoid Thoughts GPTS Questionnaire x x x
Depression BDI Questionnaire x x x
Anxiety BAI Questionnaire x x x
Stress PSS Questionnaire x x x
Self-esteem SERS Questionnaire x x x
Information processing TMT Task x x x
Demographic and clinical
background
Questions Interview x x x
Baseline diagnostic measures
Premorbid intelligence NLV Task x
Diagnostic M.I.N.I. Plus Structured Interview x
Measures during sessions Session(s)
Cyber sickness SSQ Questionnaire S3
Emotions Questions Questionnaire VRelax: each session (2x)
Performance on VR task Social cognition tasks in VR Task DiSCoVR: S1–9
Behavior in VR Reaction time, interpersonal distance Task DiSCoVR: S1–9
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The total score is used for analysis. The NLV is only ad-
ministered at baseline.
Eligibility check Mini International Neuropsychiatric
Interview Plus (M.I.N.I.-plus) [18]. A structured clinical
interview on symptoms of psychosis, depression and
mania. The MINI-plus is administered at baseline to ver-
ify a diagnosis of psychotic disorder, if a diagnosis has
not been determined by a structured clinical interview in
the past three years.
Measures during treatment sessions
Cyber sickness Simulator Sickness Questionnaire (SSQ)
[33]. A self-report questionnaire on 27 common symp-
toms of simulator sickness (e.g., headache, nausea, dizzi-
ness), which will be administered right after the VR
session 3 of both interventions to evaluate negative side
effects of using VR. We will use the total score for
analysis.
Performance and behavior during VR tasks In the
DiSCoVR group, the VR program will log several param-
eters during practice sessions (e.g., the avatars encoun-
tered, answers given to questions, time taken to answer,
the number of answer attempts and interpersonal
distance).
Emotions before and after relaxation In the VRelax
group, before and after each session in VR, participants
complete a short questionnaire in which they rate their
emotions (relaxed, anxious, gloomy, tranquil, stressed,
excited, nervous and content) on a 0–100 VAS.
Assessment
The assessments are carried out by trained, independent
research assistants. This study is single-blind, meaning
that research assistants do not know to which interven-
tion participants have been assigned. This is achieved by
instructing coordinators, therapists and participants not
to divulge group allocation to research assistants. Other
precautions include storing data revealing group alloca-
tion (e.g., therapist worksheets) in a separate location
and using different assistants for each measurement as
much as possible. Blinding is evaluated with a self-report
form for research assistants at the end of the post-treat-
ment and follow-up assessments. We will perform a sen-
sitivity analysis by testing the treatment effect only for
measurements where research assistants reported being
completely blinded to group allocation.
Randomization procedure
We utilized permuted block randomization with ran-
domized block sizes (2, 4 or 6) using the R package
‘blockrand’ [34]. For each participating treatment center,
we created strata for age (ten-year increments) and gen-
der (i.e., ten strata per center). This resulted in a master
randomization list with either ‘A’ or ‘B’ in each stratum.
An independent employee then added an additional
randomization by assigning DiSCoVR or VRelax to ei-
ther A or B in the master randomization list using coin
flips, once for each treatment center. Upon completing
T0, the participants will be placed in the appropriate
stratum in order of inclusion by the independent ran-
domizer, determining their group assignment.
Protocol fidelity
Therapists in both conditions will complete an eight-
hour training. Monthly group supervision, in which all
ongoing cases are discussed, will be provided for both
conditions, to aid therapists and improve protocol fidel-
ity. Therapists who are unavailable for these meetings
will receive individual supervision. A weekly consultation
session with the research team will also be available.
After each session, therapists will complete a session
form, on which they indicate whether they completed all
parts of the protocol for that session, and whether any
anomalies occurred.
Drop-out
Participants will be able to discontinue the study at any
point. They can also refuse participation in part of the
study, such as the ESM questionnaires. For sensitivity
analyses, participants will be considered treatment com-
pleters if they complete twelve sessions or more (> 75%).
If participants drop out of treatment, they are asked to
continue the assessments. If participants refuse or miss
T1, they are still contacted for T2.
Data management
Participant data will be coded using a study ID. Personal
information and informed consent will be stored separ-
ately to ensure anonymity. We will use an electronic
case report form; paper source data will be stored se-
curely at each respective location. An independent
monitor, who performs yearly routine inspections, will
be appointed to ensure study quality and integrity.
Analysis
For our primary outcome variables (theory of mind and
emotion perception), previous meta-analyses [6, 7] have
found effect sizes ranging between moderate (d = .46, the-
ory of mind) and large (d = .84, emotion perception). We
therefore assumed a conservative effect size of .5. With
β = .80, α = .05, two groups and three assessments, we
found we would need 86 participants. Assuming a drop-
out rate of 13% [35], we concluded that the sample should
consist of 100 participants (50 in each group).
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The groups will be compared at baseline using t-tests
for normally distributed variables, and Mann-Whitney
U-test or χ2 test for other variables. Variables with a sig-
nificant baseline difference between the groups will be
added to the analysis as a covariate.
We will use multilevel mixed-model linear regression
analysis in accordance with the intention to treat principle,
with repeated assessments (level 1) nested within partici-
pants (level 2). Time and group and their interaction term
will be included as fixed effects. Treatment effects will be
evaluated by examining the interaction between time and
group. A random intercept will be included for the partici-
pant level to account for the repeated measures. A random
slope will be included for time if this improves the model,
according to the AIC value. The post-treatment and fol-
low-up assessments will be analyzed separately, comparing
each to the baseline. We will also perform a multilevel re-
gression analysis on treatment completers, defined as
people who have completed at least twelve sessions (75%)
of their allocated intervention. Furthermore, moderator
(e.g., clinical and demographic variables) and mediator
analyses will also be conducted. Significance will be ac-
cepted at α = .05 (two-tailed); in case of multiple measure-
ments within the same domain, a correction will be
applied to α.
Procedure
Clinicians will approach potential participants and gauge
their interest in the study. If patients express interest, or if
potential participants approach the research team directly,
they will be contacted and screened by the research team.
They will receive written information about the study and
will be given a one-week consideration period. If they are
still interested after this period, participants will provide
written informed consent, collected by the research assist-
ant, and the baseline assessment will take place. In the
week after the first assessment, the baseline ESM ques-
tionnaire period will take place. After this, participants are
randomized to either DiSCoVR or VRelax, and receive six-
teen DiSCoVR or VRelax sessions. When treatment has
been completed, the post-treatment assessment will take
place, followed by another ESM period of one week. Fi-
nally, three months after completing treatment, partici-
pants will complete the last follow-up assessment,
followed by the final ESM questionnaire week.
Discussion
The main goal of this trial is to evaluate the effect of DiS-
CoVR on social cognition and social functioning. We
hypothesize that the DiSCoVR group will show greater im-
provements in emotion perception and theory of mind than
VRelax at post-treatment, and that this difference will be
maintained at 3-month follow-up. Additionally, we expect
that participants in the DiSCoVR group will experience
greater improvement in social functioning, as measured by
an interview (PSP). Furthermore, we hypothesize that people
in the DiSCoVR group will show more improvement in
daily-life social functioning (i.e., feelings of acceptance, sub-
jective social cognition, social participation and social initia-
tive) than people who receive VRelax. Since VRelax targets
stress, anxiety, coping and stress reactivity, we expect that
participants in the control group will show equal or larger
improvements in perceived stress and general anxiety.
Very little is currently known about mediators and mod-
erators of treatment effects of SCT [4]. Therefore, medi-
ation and moderation analyses will be explorative in
nature. A meta-analysis on SCT [6] found that illness dur-
ation and education level were moderators of treatment
effects on social cognition. We therefore postulate that
these variables may moderate the treatment outcome of
DiSCoVR, but we will also investigate other moderators
(e.g., baseline levels of social anxiety and paranoia).
However, no meta-analysis thus far has investigated
mediators of SCT efficacy. Both Eack et al. [36] and
Hogarty et al. [37] found that improvements in neuro-
cognition mediated improvements in social functioning
after Cognitive Enhancement Training, a form of SCT
targeting both social cognition and neurocognition. Neu-
rocognition may therefore be a mediator of treatment
outcome in the present study. However, since little is
currently known about mediators of SCT treatment ef-
fects, we will explore additional variables.
While SCT is not a new method, the present study in-
tends to improve upon existing methods by allowing par-
ticipants to apply social cognition in personalized virtual
environments and situations resembling daily life. This
trial will also address some of the gaps in knowledge about
SCT [4], particularly concerning generalization to daily life
and durability, but also moderators and mediators of
training effects.
Since there are presently no RCTs on VR SCT, the present
study will shed light on the efficacy of this innovative
method. If it proves to be effective, it could be an important
tool to improve social cognition and social functioning –
which is sorely needed, since durable functional recovery
after psychosis is still uncommon [38]. Finally, because social
cognitive deficits are a transdiagnostic characteristic [39], VR
SCT may be a useful tool to remediate problems in social
cognition and social functioning across a range of psychiatric
populations, such as autism spectrum disorders.
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